Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation

Transplantation

Volumn 97, Issue 6, 2014, Pages 694-701

  Nagai, Shunji ^a   Abouljoud, Marwan S ^a   Kazimi, Marwan ^a   Brown, Kimberly A ^a   Moonka, Dilip ^a   Yoshida, Atsushi ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Antitumor immunity; Hepatocellular carcinoma; Liver transplantation; Lymphocyte

Indexed keywords

ALBUMIN; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; HUMAN; HYPOALBUMINEMIA; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TRANSPLANTATION; LUNG METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MODEL FOR END STAGE LIVER DISEASE SCORE; NEUTROPHIL COUNT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REOPERATION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; TUMOR INVASION;

CARCINOMA, HEPATOCELLULAR; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOPENIA; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896635393     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000437426.15890.1d     Document Type: Article

References (36)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
2. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
3. D'Amico F, Schwartz M, Vitale A, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-To-seven criteria. Liver Transpl 2009; 15: 1278.
4. Llovet JM, Fuster J, Bruix J, Group B-CLC. The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10(2 Suppl 1): S115.
5. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006: CD005033.
6. Katz SC, Shia J, Liau KH, et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 2009; 249: 617.
7. Ojima T, Iwahashi M, Nakamori M, et al. Association of allogeneic blood transfusions and long-Term survival of patients with gastric cancer after curative gastrectomy. J Gastrointest Surg 2009; 13: 1821.
8. Nagai S, Fujii T, Kodera Y, et al. Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas. Pancreas 2011; 40: 3.
9. Kaido T, Takada Y, Egawa H, et al. The influence of intraoperative homologous blood transfusion on prognosis after liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 808.
10. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009; 69: 5383.
11. O'Keefe SJ, El-Zayadi AR, Carraher TE, et al. Malnutrition and immuno-incompetence in patients with liver disease. Lancet 1980; 2(8195 pt 1): 615.
12. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: Friends or foes? Lab Invest 2006; 86: 231.
13. Unitt E, Rushbrook SM, Marshall A, et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells. Hepatology 2005; 41: 722.
14. Unitt E, Marshall A, Gelson W, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45: 246.
15. Okano K, Maeba T, Moroguchi A, et al. Lymphocytic infiltration surrounding liver metastases from colorectal cancer. J Surg Oncol 2003; 82: 28.
16. Setälä LP, Kosma VM,Marin S, et al. Prognostic factors in gastric cancer: The value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 1996; 74: 766.
17. Aaltomaa S, Lipponen P, Eskelinen M, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992; 28A: 859.
18. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328.
19. Fu J, Zhang Z, Zhou L, et al. The impairment of CD4(+) cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 2013; 13: 1549.
20. Ishiyama K, Ohdan H, Ohira M, et al. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006; 43: 362.
21. Kanda M, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 2011; 98: 268.
22. Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-Analysis. Liver Transpl 2012; 18: 62.
23. Feng YX, Wang T, Deng YZ, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 2011; 53: 483.
24. Mangus RS, Fridell JA, Vianna RM, et al. Immunosuppression induction with rabbit anti-Thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-Term follow-up. Liver Transpl 2012; 18: 786.
25. Romo EM, Muñoz-Robles JA, Castillo-Rama M, et al. Peripheral blood lymphocyte populations in end-stage liver diseases. J Clin Gastroenterol 2007; 41: 713.
26. Cereda E, Pusani C, Limonta D, et al. The association of Geriatric Nutritional Risk Index and total lymphocyte count with short-Term nutrition-related complications in institutionalised elderly. J Am Coll Nutr 2008; 27: 406.
27. Nozoe T, Ninomiya M, Maeda T, et al. Prognostic nutritional index: A tool to predict the biological aggressiveness of gastric carcinoma. Surg Today 2010; 40: 440.
28. Ferreira LG, Anasta'cio LR, Correia MI. The impact of nutrition on cirrhotic patients awaiting liver transplantation. Curr Opin Clin Nutr Metab Care 2010; 13: 554.
29. Hasse JM, Blue LS, Liepa GU, et al. Early enteral nutrition support in patients undergoing liver transplantation. JPEN J Parenter Enteral Nutr 1995; 19: 437.
30. Kaido T, Ogawa K, Fujimoto Y, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant 2013; 13: 1549.
31. Aizawa M, Gotohda N, Takahashi S, et al. Predictive value of baseline neutrophil/lymphocyte ratio for T4 disease in wall-penetrating gastric cancer. World J Surg 2011; 35: 2717.
32. Huang ZL, Luo J, Chen MS, et al. Blood neutrophil-To-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2011; 22: 702.
33. Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophillymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141.
34. Bertuzzo VR, Cescon M, Ravaioli M, et al. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011; 91: 1279.
35. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 539.
36. Coussens LM,Werb Z. Inflammation and cancer. Nature 2002; 420: 860.